未接种疫苗女性首轮HPV筛查的年龄别结局:英国宫颈筛查试点观察性研究
该观察性研究基于2013-2016年英国六个NHS实验室站点共1,341,584名接受高危HPV检测或液基细胞学筛查的女性,随访至2019年底,报告年龄别筛查结局。24-29岁组HPV阳性率26.9%、直接转诊阴道镜比例10.4%、CIN2+阳性预测值47%,50-64岁组分别为5.3%、1.2%和27%。结论认为数据为未来流行病学研究提供可靠参考。
要点
- 24-29岁组HPV阳性率26.9%,50-64岁组仅5.3%。
- 直接转诊阴道镜比例24-29岁组10.4%,50-64岁组1.2%。
- CIN2+阳性预测值24-29岁组47%,50-64岁组27%。
核心结论
- 这些数据为未来流行病学研究(包括HPV疫苗接种效果研究)提供了可靠参考。
研究设计与样本
- 观察性研究,筛查于2013-2016年进行,随后进行两次早期召回和/或阴道镜检查直至2019年底。
- 共纳入1,341,584名接受高危HPV检测或液基细胞学筛查的女性,来自六个NHS实验室站点。
主要发现
- 24-29岁接受HPV检测的女性中,26.9%检测阳性,10.4%经细胞学分流后直接转诊阴道镜,CIN2+阳性预测值为47%。
- 50-64岁组相应比例分别为5.3%、1.2%和27%。
- 无细胞学异常的HPV阳性女性中,早期召回HPV检测转阴的比例在24-29岁组为54%,50-64岁组为55%。
- 任何年龄组中约三分之二的感染与非16/18型别相关;但在CIN2、CIN3或宫颈癌女性中,非16/18型别感染比例随年龄增加。
- 液基细胞学筛查检出的异常比例低于HPV检测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report detailed age-specific outcomes from the first round of an English pilot studying the implementation of high-risk human papillomavirus (HR-HPV) testing in primary cervical screening. DESIGN: Observational study with screening in 2013-2016, followed by two early recalls and/or colposcopy until the end of 2019. SETTING: Six NHS laboratory sites. POPULATION: A total of 1 341 584 women undergoing screening with HR-HPV testing or liquid-based cytology (LBC). METHODS: Early recall tests and colposcopies were recommended, depending on the nature of the screening-detected abnormality. MAIN OUTCOME MEASURES: We reported standard screening process indicators, e.g. proportions with an abnormality, including high-grade cervical intraepithelial neoplasia (CIN2+) or cancer, and the positive predictive value (PPV) of colposcopy for CIN2+, by screening test and age group. RESULTS: Among unvaccinated women screened with HR-HPV testing at age 24-29 years, 26.9% had a positive test and 10.4% were directly referred to colposcopy following cytology triage, with a PPV for CIN2+ of 47%. At 50-64 years of age, these proportions were much lower: 5.3%, 1.2% and 27%, respectively. The proportions of women testing positive for HR-HPV without cytological abnormalities, whose early recall HR-HPV tests returned negative results, were similar across the age spans: 54% at 24-29 years and 55% at 50-64 years. Two-thirds of infections at any age were linked to non-16/18 genotypes. Among women with CIN2, CIN3 or cervical cancer, however, the proportion of non-16/18 infections increased with age. As expected, the detection of abnormalities was lower following screening with LBC. CONCLUSIONS: These data provide a reliable reference for future epidemiological studies, including those concerning the effectiveness of HPV vaccination. TWEETABLE ABSTRACT: Data from the English pilot study provide a comprehensive overview of abnormalities detected through HPV screening.
引用
- Rebolj M, Mathews CS, Pesola F, et al. Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot. BJOG. 2022. PMID: 34913243. doi:10.1111/1471-0528.17058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。